Assenagon Asset Management S.A. Buys Shares of 4,425 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Assenagon Asset Management S.A. acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,425 shares of the medical research company's stock, valued at approximately $1,078,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Venturi Wealth Management LLC increased its holdings in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after acquiring an additional 87 shares during the last quarter. GeoWealth Management LLC boosted its holdings in Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after purchasing an additional 72 shares during the period. Picton Mahoney Asset Management boosted its holdings in Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares during the period. Curat Global LLC bought a new stake in Bio-Rad Laboratories during the first quarter valued at $34,000. Finally, Cape Investment Advisory Inc. acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth $38,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on BIO shares. UBS Group decreased their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a research note on Monday, June 9th. Wall Street Zen lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, June 8th. Royal Bank Of Canada cut their price target on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Finally, Citigroup reduced their price objective on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $324.25.

Bio-Rad Laboratories Stock Performance

NYSE:BIO traded up $4.11 during mid-day trading on Friday, hitting $236.11. The stock had a trading volume of 1,487,428 shares, compared to its average volume of 376,618. The company has a current ratio of 5.99, a quick ratio of 4.43 and a debt-to-equity ratio of 0.18. The company has a 50 day simple moving average of $235.73 and a 200-day simple moving average of $278.06. The stock has a market capitalization of $6.42 billion, a price-to-earnings ratio of -3.10 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, beating the consensus estimate of $1.73 by $0.81. The company had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. Bio-Rad Laboratories's revenue was down 4.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.30 earnings per share. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.